<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405873</url>
  </required_header>
  <id_info>
    <org_study_id>AMT/P2GI/001 Part I</org_study_id>
    <secondary_id>LC004AURON2005</secondary_id>
    <nct_id>NCT00405873</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003</brief_title>
  <official_title>A Prospective, Open, Single-arm, Multicenter Phase II Clinical Trial to Evaluate the Tumour Response and Safety in Patients With Advanced Primary Hepatocellular Carcinoma Treated With AMT2003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auron Healthcare GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auron Healthcare GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer
      patients with advanced primary hepatocellular carcinoma

      The primary endpoint is best overall response rate within 20 weeks after registration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with advanced primary hepatocellular carcinoma refractory to
      standard therapy or for which no effective standard therapy exists.

      The best overall response rate is the best response recorded from the start of treatment
      until disease progression / recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later</measure>
    <time_frame>March 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) time</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) time</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC QLQ-C30) and Performance Status (Karnofsky Index)</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>March 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AMT2003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMT2003</intervention_name>
    <arm_group_label>AMT2003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer confirmed by histology or cytology

          -  At least one measurable lesion

          -  Advanced disease refractory to standard therapy or for which no standard therapy
             exists

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Known secondary neoplasia or central nervous system (CNS) metastases; acute or chronic
             leukemia, lymphoma or multiple myeloma

          -  Body weight below 45 kg

          -  Female patients who are pregnant or breast feeding or adults of reproductive potential
             not employing effective method of birth control

          -  Confirmed diagnosis of HIV

          -  Insulin dependent diabetes mellitus / abnormal glucose tolerance test (GTT) / latent
             diabetes mellitus type I or II

          -  Chemotherapy or radiotherapy less than 4 weeks prior to entry

          -  Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)

          -  Participation in a clinical trial less than 30 days prior to entry into study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Blum, Prof. Dr. med. Dr. h. c.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Freiburg, Dept. of Internal Medicine II</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baaden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic SanaFontis</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.alpiniainstitute.com</url>
    <description>Now legally responsible for study</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary hepatocellular carcinoma</keyword>
  <keyword>Liver cancer</keyword>
  <keyword>Tumour response</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

